Clinical Trails

Early results from an ongoing phase 1/2 clinical trial show promising activity for vopimetostat, an oral PRMT5 inhibitor, when combined with RAS-targeted therapies in patients with advanced, previously treated pancreatic cancer that has an MTAP deletion. The strongest results were seen with vopimetostat plus daraxonrasib in patients with RAS-mutant pancreatic cancer. Among 12 evaluable patients, […]

The phase 3 RECITE trial evaluated romiplostim (Nplate) versus placebo for chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal cancers receiving oxaliplatin-based chemotherapy. CIT often forces chemotherapy delays or dose reductions, potentially compromising treatment effectiveness. Romiplostim significantly improved treatment continuity. Eighty-four percent of patients receiving romiplostim required no CIT-related chemotherapy dose modifications during cycles 2 and

Long-term results from the phase 3 NCT01812902 tria suggest that extended pelvic lymph node dissection (ePLND) during radical prostatectomy may provide a significant survival benefit for patients with high-grade prostate cancer. The study enrolled 300 men with intermediate- or high-risk prostate cancer and followed them for a median of nearly 11 years. While extended lymph node

Results from the phase 3 RINGSIDE trial showed that varegacestat (AL102) significantly improved outcomes for patients with progressing desmoid tumors. The findings have supported a New Drug Application submitted to the FDA in April 2026. The global study enrolled 156 adults with desmoid tumors that had progressed within the previous year and randomly assigned them

A phase 2 clinical trial found that adding the PD-1 inhibitor sintilimab to adjuvant capecitabine did not improve outcomes for patients with locoregionally advanced nasopharyngeal carcinoma who responded poorly to induction chemotherapy. The study enrolled 152 high-risk patients and randomly assigned them to receive either sintilimab plus capecitabine or capecitabine alone after chemoradiotherapy. The trial

A Phase II clinical trial has found that sacituzumab govitecan, an FDA-approved breast cancer drug, may offer a promising new treatment option for advanced uterine cancer. The study enrolled 50 patients whose disease had progressed despite standard therapies. Researchers reported that 70% of participants experienced tumor shrinkage, while 28% achieved a significant reduction of at

A Phase II clinical trial conducted by researchers at the Yale School of Medicine has identified a promising new treatment for advanced uterine cancer using sacituzumab govitecan, a drug already approved for breast cancer. The study included 50 patients whose cancer had progressed after standard therapies. Results showed that 70% of participants experienced tumor shrinkage,

Interim results from the Phase 2/3 Duravelo-2 trial show that zelenectide pevedotin (BT8009) combined with pembrolizumab demonstrates strong anti-tumor activity and improved tolerability in patients with locally advanced or metastatic urothelial carcinoma. Zelenectide pevedotin is a “Bicycle drug conjugate” designed to penetrate tumors rapidly and clear quickly from healthy tissue, reducing the severe side effects commonly

Findings from the StrateGIST 1 trial show that velzatinib (IDRX-42), a broad-spectrum oral therapy, demonstrates strong clinical activity across multiple lines of treatment in patients with advanced gastrointestinal stromal tumors (GIST). The drug is designed to overcome resistance driven by KIT gene mutations, which account for about 75% to 80% of GIST cases. While current therapies

Findings from the Phase 3 SARC041 trial show that abemaciclib (Verzenio) significantly delays disease progression in patients with advanced dedifferentiated liposarcoma (DD-LPS), a rare and aggressive soft-tissue cancer. The drug targets CDK4, a protein amplified in nearly all DD-LPS cases that drives tumor growth. By inhibiting this pathway, abemaciclib slows cancer progression more effectively than